Elizabeth Berry-Kravis
Elizabeth Berry-Kravis MD, PhD is a Professor of Pediatrics and Neurological Sciences at Rush
University Medical Center in Chicago. She established the Fragile X Clinic and Research
Program in 1991, through which she has provided care to over 800 patients with fragile X
syndrome (FXS). She has studied medical issues, epilepsy and psychopharmacology in FXS,
and has been a leader in translational research in FXS for 20 years, including development of
clinical outcome measures and biomarkers, natural history studies, newborn screening, and
particularly clinical trials of new targeted treatments in FXS, for which she has been PI or Co-PI
of 27 trials, both industry and investigator sponsored. Her laboratory studies the cellular role of
fragile X messenger ribonucleoprotein (FMRP), relationship between FMRP and clinical
function, and optimization of genetic testing methods. More recently she has expanded clinical
and translational work to other neurodevelopmental disorders in addition to FXS, including
autism spectrum disorders and single gene models of ASD, including Phelan McDermid
syndrome, Rett syndrome, and Angelman syndrome. She also is working on translational
research in rare neurogenetic disorders including Niemann-Pick type C, Battens disease,
pantothenate kinase-associated neurodegeneration, and creatine transporter deficiency, as well
as N-of-1 trials of ASOs and gene therapy for early onset epileptic encephalopathies and other
neurogenetic conditions. She has received the NFXF Jarrett Cole Clinical Award, FRAXA
Champion Award, NFXF William and Enid Rosen Research Award, March of Dimes Jonas Salk
Research Award, American Academy of Neurology Sidney Carter Award in Child Neurology,
John Merck Fund Sparkplug Award, the FRAXA Ingenuity Award, the FAST Innovation Award,
the inaugural Martha Bridge Denckla Award from the Child Neurology Society for work in
cognitive disorders of children, and the CureSHANK 2025 PMS Investigator of the Year Award.
Abstracts this author is presenting: